The hedgehog pathway and pancreatic cancer

New England Journal of Medicine

Volumn 361, Issue 21, 2009, Pages 2094-2096

  Hidalgo, Manuel ^a   Maitra, Anirban ^b  

^a Centro Nacional de Investigaciones Oncológicas   (Spain)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE; IPI 926; SMOOTHENED PROTEIN; SONIC HEDGEHOG PROTEIN; UNCLASSIFIED DRUG;

CANCER STEM CELL; HUMAN; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; OUTCOME ASSESSMENT; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN BINDING; SHORT SURVEY; XENOGRAFT;

ANIMALS; DISEASE MODELS, ANIMAL; HEDGEHOG PROTEINS; HUMANS; MICE; PANCREATIC NEOPLASMS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; VERATRUM ALKALOIDS;

EID: 70949096151     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcibr0905857     Document Type: Article

References (5)

1. Von Hoff DD, LoRusso PM, Rudin CM, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009;361:1164-1172
2. Olive KP, Jacobetz MA, Davidson CJ, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 2009;324:1457-1461
3. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806
4. Feldmann G, Habbe N, Dhara S, et al. Hedgehog inhibition prolongs survival in a genetically engineered mouse model of pancreatic cancer. Gut 2008;57:1420-1430
5. Jimeno A, Feldmann G, Suárez-Gauthier A, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. Mol Cancer Ther 2009;8:310-314